Source: Pharmacy Times articles
Discontinuing lenalidomide after 3 years of MRD negativity shows low relapse rates in multiple myeloma, offering hope for treatment-free remission.
by MM360 Staff | Aug 5, 2025 | Myeloma News | 0 comments
Source: Pharmacy Times articles
Discontinuing lenalidomide after 3 years of MRD negativity shows low relapse rates in multiple myeloma, offering hope for treatment-free remission.